“Abbott India: The ₹35K Pharma Stock That Prescribes Dividends (and Premium Valuations)”
Date of Publishing -
Spotted a factual error — a wrong number, date, or fact? Tell us and we will check the source.
1. At a Glance
Abbott India is the OG MNC pharma player that doesn’t chase headlines, but quietly compounds at double digits. With ROCE at 46%, zero debt, and 70%+ dividend payout, this is the HDFC Bank of pharma. Just don’t expect fireworks—this is more Sanjay Bakshi than Reddit trader.
2. WTF Do They Even Do?
Abbott India Ltd is the Indian subsidiary of Abbott Laboratories (USA) and handles:
🧪 Branded Generics (dominated by top brands like Thyronorm, Duphaston) 💊 Prescription Pharma in segments like:
Gastro (antacids, PPIs)
CNS
Women’s Health
Nutraceuticals
Pediatric vaccines (PCV-14 just launched)
👉 It doesn’t manufacture everything itself; much is outsourced or co-developed globally.
3. Financials Overview – Not Fast, But Furious(ly Profitable)
Metric
FY21
FY22
FY23
FY24
FY25
Revenue (₹ Cr)
4,310
4,913
5,349
5,849
6,409
Net Profit (₹ Cr)
691
799
949
1,201
1,414
OPM (%)
21%
22%
23%
25%
26%
ROCE (%)
35%
38%
41%
46%
46%
ROE (%)
32%
34%
36%
36%
35.7%
🧠 TL;DR: Margin gains are real. This is one of India’s most capital-efficient pharma stocks.
